Abstract: EGFR, a receptor tyrosine kinase often mutated in cancer, has variants affecting its structure, signalling, drug interactions, and treatment response in non-small cell lung cancer. This study introduces a combined NGS and Bio python-based computational method for identifying and mapping EGFR variants using PDB ID: 8D76. NGS data helps......
Keywords: EGFR variants, Next-generation sequencing (NGS), Bio-python, Structural bioinformatics, Molecular docking, Targeted therapy, ADMET analysis, Tyrosine kinase
[1]. Siegel, R. L., Miller, K. D., Wagle, N. S., & Jemal, A. (2023). Cancer statistics, 2023. CA: A Cancer Journal for Clinicians, 73, 17–48.
[2]. Alsaed, B., Bobik, N., Laitinen, H., et al. (2025). Shaping the battlefield: EGFR and KRAS tumor mutations’ role on the immune microenvironment and immunotherapy responses in lung cancer. Cancer Metastasis Reviews, 44, 56. https://doi.org/10.1007/s10555-025-10272-4
[3]. Bhoomika, A., Kumari, U., & Bhavana, K. S. (2023). In silico computer-aided drug designing of the mutated EGFR kinase domain of NSCLC (non-small cell lung cancer). Journal of Emerging Technologies and Innovative Research, 10(12), B226–B235.
[4]. Szklarczyk, D., Kirsch, R., Koutrouli, M., Nastou, K., Mehryary, F., Hachilif, R., Gable, A. L., Fang, T., Doncheva, N. T., Pyysalo, S., Bork, P., Jensen, L. J., & von Mering, C. (2023). The STRING database in 2023: Protein–protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Research, 51(D1), D638–D646. https://doi.org/10.1093/nar/gkac1000.